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Introduction
45
Heart failure is a major cause of morbidity and mortality worldwide [1, 2] . The 46 prevalence and incidence of heart failure are increasing [3, 4] , and the constant shortage of donor organs increases the need for alternatives to heart transplant in patients with end-stage 48 heart failure refractory to medical treatment [5] . Currently, around 2% of the adult population 49 in developed countries suffers from heart failure [6] .
50
In this context, the advent of implantable left ventricular assist device (LVAD) 51 represents a major medical progress for end-stage heart failure in selected patients [7, 8] , and 52 is currently used as a bridge-to-heart transplantation, a bridge-to-recovery, or as destination 53 therapy (i.e., as the last resort in patients with neither perspectives of recovery, nor heart 54 transplant). Implantable LVAD intended for long-term use rely on a percutaneous driveline, 55 to carry electric signals and energy from the controller and batteries to the implanted pump.
56
As with any other implantable foreign device, LVAD is subject to LVAD-related infections, 57 a consequence of medical progress that is gradually emerging, proportionally to the number 58 of patients implanted with LVAD [9, 10] . Indeed, the presence of a driveline piercing the skin 59 places the patient at a continuous risk for infections, that can affect the exit site, the 60 subcutaneous tunnel, the abdominal pocket (if present), the implanted pump, and disseminate 61 through bloodstream infections. The transition from pulsatile to continuous-flow LVAD 62 significantly improved clinical outcome [11] , and decreased the risk of infectious 63 complications, but LVAD-related infections are still common [12, 13] . Due to the scarcity of 64 data currently available in the medical literature, the management of these emerging 65 infections is poorly standardized, and mostly derives from the state-of-the-art for the 
180
To our knowledge, few studies have reported the incidence, the characteristics, and 181 the management of LVAD-related infections thus far. Previous reports found an incidence of 182 LVAD-related infections similar to our cohort, but with a median time from LVAD 183 implantation that was slightly longer, at 4.4 to 7.4 months [13, 15] , as compared to 2.9 months 184 in our study. These discrepancies may be related to the close monitoring routinely 185 implemented after LVAD implantation in our centers, to limited sample size, or to the fact 186 that 58% of our patients were classified as INTERMACS I by the time of implantation, which 187 has been associated with earlier first pump-related infection [16] . Microbiological 
